Media headlines about Codexis (NASDAQ:CDXS) have been trending somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Codexis earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.655406975824 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of research firms have commented on CDXS. BidaskClub upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright restated a “buy” rating and set a $8.50 price target on shares of Codexis in a research report on Tuesday, November 21st. Jefferies Group lifted their price objective on shares of Codexis from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday, October 13th. Zacks Investment Research raised shares of Codexis from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, ValuEngine raised shares of Codexis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $7.50.
Shares of Codexis (CDXS) traded up $0.02 on Monday, reaching $6.95. 251,048 shares of the company were exchanged, compared to its average volume of 170,035. Codexis has a 52-week low of $3.60 and a 52-week high of $7.95.
In other Codexis news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of Codexis stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $5.78, for a total value of $6,126,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.80% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/05/codexis-cdxs-given-daily-media-impact-rating-of-0-14.html.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.